Kumar Sambamurti on Missing ‘Lnc’? Long Noncoding RNAs Bind Tau, Tame Stress Granules

COMMENT This is a really thorough write-up of an exciting finding. sambak 0

Markus Damme on Endolysosomal TMEM106b Regulates Myelin Lipid Metabolism

COMMENT A point mutation in TMEM106B causes a rare form of hypomyelinating leukodystrophy (HLD) (Simons et al., 2017), but how it does so is unknown. Therefore, it is critical to understand TMEM106b’s physiological function. It was speculated from the AlphaFold-p

Benjamin Wolozin on Missing ‘Lnc’? Long Noncoding RNAs Bind Tau, Tame Stress Granules

COMMENT This is is a very elegant study with very interesting results. First I want to note the elegant design of this study. Bhagat and colleagues examine lncRNAs among multiple iPSC lines harboring exon 10 mutations and identify a series of lncRNAs that show co

Julia TCW on Astrocyte Receptor Suppresses Neurotoxic Lipids, Preserves Neurons

COMMENT Zhang et al. identified one target, human astrocyte-specific protein, TMEM164, which is suppressed in major neurodegenerative diseases including AD, PD, HD, MS, ALS, and FTLD patient brains through unbiased screening of overlapping molecules among these n

Radosveta Koldamova on Healthy CSF Teems with Diverse Lipoproteins

COMMENT Aberrant lipid metabolism has been linked to several neurodegenerative diseases but, unfortunately, knowledge of the lipoprotein particles in CSF (CSF-Lps) is limited. The main obstacle is their much smaller concentration in CSF than plasma, which prohibi

George Kannarkat on Meet the Two New Biomarker Candidates for Lewy Body Diseases

COMMENT Two recent publications have identified novel biomarkers for PD based on pathways that have long been known to be associated with its pathogenesis (Qi et al., 2023). Interestingly, these biomarkers also reflect changes in blood that are concurrently repor

Douglas Galasko on Meet the Two New Biomarker Candidates for Lewy Body Diseases

COMMENT Protein biomarkers for Parkinson’s disease and DLB have been sought extensively, with far fewer hits than in AD. Recent efforts using the O-link multiplex immune-PCR assay system for discovery have yielded interesting results. In a large, multicenter CSF

Brit Mollenhauer on Meet the Two New Biomarker Candidates for Lewy Body Diseases

COMMENT This is an exciting time, not only with the robust seed amplification assays showing high sensitivities and specificities in cerebrospinal fluid of neuronal synuclein disorders, but also with emerging blood biomarkers. DDC indeed has been identified befor

Lawren VandeVrede on Meet the Two New Biomarker Candidates for Lewy Body Diseases

COMMENT This is an interesting set of papers. Qi et al. extends these authors’ prior work shedding light on the pathobiology of PD, particularly carriers of pathogenic LRKK2 variants. A blood-based biomarker is critically needed for synucleinopathies, as current

Sagar Gaikwad on Astrocyte Receptor Suppresses Neurotoxic Lipids, Preserves Neurons

COMMENT It’s exciting to see advancements in research that could lead to innovative clinical interventions. This study provides the first evidence of a regulatory role of TMEM164 in astrocyte activation within the nervous system. The study reported that TMEM164 o

Hermona Soreq on When Faced with Amyloidosis, Human Transplants Die by Necroptosis

COMMENT I found this study to be of major interest, for several reasons. The de Strooper team implanted female H9 stem cell-originated neurons in the brains of AD mouse models, which displayed multiple AD biomarkers and overexpression of the longest splice varian

Luc Nwamekang Belinga on CSF Proteomic Panel Better Predicts Decline Than Do Classic AD Biomarkers

COMMENT Impressive work that aligns with previous studies on proteomics CSF analysis for Alzheimer's disease (AD). The use of panels, which combine signatures from various proteins, could potentially be the key to improving the accuracy of AD diagnosis, moni

Erika Di Biase, Ole Isacson on Healthy CSF Teems with Diverse Lipoproteins

COMMENT The key contribution of this work is the description of the novel method combining fluorescent phospholipid labeling with tandem size-exclusion chromatography to investigate the composition of CSF lipoproteins at a high resolution. LC-MS/MS proteomic anal

Domenico Pratico on When Faced with Amyloidosis, Human Transplants Die by Necroptosis

COMMENT Described for the first time more than 100 years ago, brain shrinkage secondary to cell loss together with Aβ plaques and tau tangles is one of the three major features of Alzheimer's disease pathology. While in the last 25 years we have been able to

Manu Goyal on CSF Proteomic Panel Better Predicts Decline Than Do Classic AD Biomarkers

COMMENT This is another fascinating study of CSF proteomics, now in late-onset AD, in parallel to the recent Johnson et al. paper in autosomal-dominant AD. Once again, proteins related to metabolism—particularly glycolysis—showed strong relationships with other A